Our developing bone-targeting method using oligopeptide showed the potential for improving skeletal abnormalities in MPS IVA [21,122], and this bone-targeting strategy combined with gene therapy and new ERT should be new candidates for this disorder. This evidence concerns the gene ELF3 and mucopolysaccharidosis type 4A.